Best of Pain Management Coverage in 2022

This treatment is the first and only long-acting buprenorphine injectable with weekly and monthly doses.

A new meta-analysis found duloxetine to be the only commonly prescribed medication that was effective.

Only the 60 mg dose of atogepant is approved for chronic migraine prevention.

A new study from JAPHA explores the link between OUD and social factors.

Naloxone hydrochloride nasal spray (Narcan) 4 mg is expected to be available over the counter in late summer 2023.

Vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate for children who experience migraine attacks, showed a study conducted in Saudi Arabia.